JAMA–Why guideline making requires reform

A recent article by Sniderman and Furberg, “Why Guideline Making Requires Reform”  is a remarkably comprehensive over-view of the pitfalls of evidence based guidelines.  The article points out that guidelines are often mistaken for science when in fact their recommendations may be no more than “expert opinions”—which, of course, are subject to full spectrum of human failings, including bias, group think, and even conflicts-of-interests.   If this sounds like part of the problem with the IDSA guidelines, it should.  IDSA’s 2006 Lyme Guidelines contain 71 recommendations, of which 38 are based on no more than opinion.  

Some of the other highlights from the Sniderman article include:

Importantly, even when it is known that areas of legitimate controversy will be covered, there is often no attempt to ensure that all sides will have reasonable opportunity to present their evaluation of the evidence and participate in the decisionmaking process. . . .

 

On many, if not most, issues the evidence, no matter how extensive, remains incomplete. For example, even though the general conclusion that statins reduce the risk of vascular events is incontestable, many specifics remain debatable, such as how intensive therapy should be, when therapy should be started for different clinical situations, and which markers should be used to monitor therapy. Because gaps in the evidence are inevitable, they must be filled in with judgments, and judgments tend to preserve previous positions. Thus, what is to be decided is often already decided with the selection of the deciders. . . .

 

In summary, evidence is complex and incomplete. Therefore, when the evidence warrants, guidelines should respect diversity of views. Guidelines must be directed only to the interests of patients and not to those who profit from them. Failure to reform the guideline process risks replacing one authority-based system with another, whereas the core objective should be to strengthen an evidence-based approach to improve clinical care.

 

 

Sniderman suggests a number of reforms to the guideline development process, including:

 

Third, reports should not be issued unanimously unless all members fully agree to all sections.  Alternate interpretations and viewpoints should be recorded and issued along with the majority opinions. Fourth, posting an almost final version on the Internet and inviting commentary is an attractive model. This helps ensure that where legitimate differences of scientific opinion exist, there is an opportunity for exchange before final decisions are taken. Fifth, before publication, guidelines should undergo independent scientific review. The journal editor should present the criticisms and suggestions that result from the reviewers to the panel for its responses, and may require revision of the guideline document, as appropriate. The editor also should consider co-publishing alternate points of view as necessary.

 

Similar Posts

  • LYMEPOLICYWONK: Perception is Everything—Is it Black or White: Who decides?

    When science is uncertain, who decides what to do? Do patients get treated or are they abandoned and told to wait for research that, in the case of Lyme disease, may never come? I attended a conference in Spain this year at the Cochrane Collaboration. One of the speakers, Dr. Mary Docherty, pointed out that recommendations to deny care based solely on “insufficient evidence” could be inappropriate and harmful to patients. To illustrate the point, she used the example of an upper GI (gastro-intestinal) bleed. Suppose there are two treatment options, but there is insufficient evidence to support either one? Still, the patient with an upper GI bleed must be treated. To do otherwise, might risk death or serious disability for the patient. Such is the case with Lyme disease.

  • LYMEPOLICYWONK: IOM Report: ’Tis neither here nor there. Or?

    The Institute of Medicine (IOM) has released its long awaited report on Lyme disease. So should we celebrate or despair? I think there is room for a little of both. We should certainly celebrate the tone of the report, which characterizes the session as “a walk in the woods” to start dialogue and we should celebrate the contributions made by those who attended and participated, whether as patients, advocacy groups, researchers or physicians. I think these people did their very best to represent a side of Lyme disease that is not often given public voice. We should also recognize the contribution to a better process that was achieved by the three groups who pulled out of the hearing (CALDA, LDA, and Time for Lyme). This action resulted in Dr. Benjamin Luft of Stony Brook University being added to the agenda and may have also added to the “tone” of the report. What we should not lose sight of though, is that a civil tone and the inclusion of some patients’ testimony are not enough. This is a debate about science. Debates are about equal time, opportunities to rebut, and not excluding opposing viewpoints. That did not happen here. And, what the IOM left out or left unchallenged harms patients. Our biggest hits were in diagnosis, the exclusion of the topics chronic Lyme and treatment, and the complete exclusion of any physicians from ILADS. Let me drill down into the details.

  • IDSA Lyme Hearing: Wormser– Talk About Exaggeration!

    Talk about exaggeration. No really–at the hearing. Dr. Carol Baker asked Dr. Wormser the $200 question: Why exaggerate if the truth will do? She was talking about the use in the guidelines of words like "vast majority" when the real percentage was 65%. And her question was why not let percentages speak for themselves? If the truth is 65%–why not simply say 65%. Is it just me, or does Wormser sound irritated at the question? His response after a drill down is that he would not use the expression "vast majority" to refer to anything less than say–90%. Excuse me? Did I hear that right? 90%. Really? Ok, let's break it down for him.

  • LYMEPOLICYWONK: Ticks Transmit a World of Disease and Co-infections Into the Lives of Lyme Patients

    Ticks are the number one vector of disease in the US and are second only to mosquitoes worldwide. Ticks frequently take blood meals from small rodents like rats, squirrels, and mice, which carry diseases. Diseases they pick up from these blood meals may then be passed on to their next meal ticket–which could be you. So how many pathogens can a tick transmit? A recent study from China provides some answers.

  • The FDA and Lyme Disease Testing—FDA is Listening, but Does it Matter?

    In August last year, I blogged about new FDA guidance on laboratory developed tests and how these might restrict access to diagnosis and care for Lyme patients. Many patients with Lyme disease rely on laboratory developed tests, for example, the IGeneX western blot. Since that time, I have met with the FDA twice and LymeDisease.org conducted a survey which drew close to 8,000 responses. The results of that survey were presented to the FDA in our meetings and by Dr. Elizabeth Maloney at the FDA public hearing in January. On January 29th, LDo submitted official public comments to the FDA proposal.

  • IDSA HEARING: Follow the hearing and comment 8 a.m.-5 p.m. ET, July 30

    We are providing blog updates of testimony throughout the day.
    We will post frequent updates of the hearing testimony starting at 8 a.m. Eastern time. You can add comments at the bottom of this page. However, you must hit the refresh button on your browser periodically, so that you can see new postings and comments as they are added. If you keep this page open without refreshing it, you won’t see any of the updates.